Cerus Corporation (NASDAQ: CERS) announced today that 32 studies on the company's INTERCEPT Blood System have been accepted for presentation at the International Congress of the International Society of Blood Transfusion to be held in Macao SAR, China, June 7-12, 2008.

Cerus Corporation has said it is considering making changes to its immunotherapy unit including partnering the business or creating a possible spin off.

Cerus Corporation (NASDAQ: CERS) announced today it will explore strategic alternatives for its immunotherapy programs.

Cerus Corporation (NASDAQ:CERS) announced today the receipt of two research grants to develop vaccines based on its proprietary Listeria platforms. These grants fund early-stage work to develop vaccines to both treat and prevent infections caused by HCV and HIV.

Cerus Corporation (NASDAQ:CERS) today announced th